Vaxcyte (PCVX) Common Equity (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Common Equity of $3.0 billion for Q1 2026, down 6.38% year-over-year from $3.2 billion in Q1 2025, and up 11.56% quarter-over-quarter from $2.7 billion in Q4 2025.
Vaxcyte (PCVX) Common Equity (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Common Equity for 8 consecutive years, with $3.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 6.38% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $3.0 billion (down 6.38% YoY), while the FY2025 annual figure was $2.7 billion, down 18.76% from the prior year.
- Common Equity climbed to $3.0 billion in Q1 2026 per PCVX's latest filing, from $2.7 billion in the prior quarter.
- Across five years, Common Equity topped out at $3.4 billion in Q3 2024 and bottomed at $359.3 million in Q3 2022.
- Historically, Common Equity has averaged $1.9 billion across 5 years, with a median of $2.0 billion in 2024.
- Annual changes were most pronounced in 2023 — Common Equity soared 291.1% — and 2025, when it retreated 18.76%.
- Vaxcyte's Common Equity stood at $953.6 million in 2022, then surged by 30.08% to $1.2 billion in 2023, then jumped by 166.5% to $3.3 billion in 2024, then declined by 18.76% to $2.7 billion in 2025, then increased by 11.56% to $3.0 billion in 2026.
- Business Quant data shows PCVX's Common Equity at $3.0 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 2.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.76 Bn |
| Mar 31, 2026 | 3.00 Bn |
| Dec 31, 2025 | 2.69 Bn |
| Sep 30, 2025 | 2.89 Bn |
| Jun 30, 2025 | 3.07 Bn |
| Mar 31, 2025 | 3.20 Bn |
| Dec 31, 2024 | 3.31 Bn |
| Sep 30, 2024 | 3.42 Bn |
| Jun 30, 2024 | 1.99 Bn |
| Mar 31, 2024 | 1.98 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.40 Bn |
| Jun 30, 2023 | 1.43 Bn |
| Mar 31, 2023 | 944.77 Mn |
| Dec 31, 2022 | 953.61 Mn |
| Sep 30, 2022 | 359.31 Mn |
| Jun 30, 2022 | 366.50 Mn |
| Mar 31, 2022 | 359.54 Mn |
| Dec 31, 2021 | 284.02 Mn |
| Sep 30, 2021 | 305.96 Mn |